The extraocular muscles (EOMs) are a unique group of specialized muscles that are anatomically and physiologically distinct from other skeletal muscles. Perhaps the most striking characteristic of the EOMs is their differential sensitivity to disease. EOMs are spared in Duchenne's muscular dystrophy (DMD), despite widespread involvement of other skeletal muscles. Conversely, they are early and prominent targets in myasthenia gravis and mitochondrial myopathies. It is unclear how EOMs achieve such specialization or differential response to diseases, however, this has been attributed to a unique, group-specific pattern of geneexpression or "allotype". To begin to address these issues as well as define the human EOM allotype, we analyzed the human EOM transcriptome using oligonucleotide-based expression profiling. 338 genes were found to be differentially expressed in EOM compared to Quadriceps femoris limb muscle, using a twofold cutoff. Functional characterization revealed expression patterns corresponding to known metabolic and structural properties of EOMs such as expression of EOM-specific myosin heavy chain (MYH13), high neural, vascular and mitochondrial content, suggesting the profiling was sensitive and specific. Genes related to myogenesis, stem cells and apoptosis were detected at high levels in normal human EOMs, suggesting that efficient and continuous regeneration and/or myogenesis may be a mechanism by which the EOMs remain clinically and pathologically spared in diseases such as DMD. Taken together, this study provides insight of how human EOMs achieve their unique structural, metabolic and patho-physiological properties.
Introduction
The extraocular muscles (EOMs) are a group of unique skeletal muscles that are required to locate and accurately track objects by the visual system. The EOMs faithfully, rapidly and accurately effectuate a variety of reflex and voluntary eye movements. The functional requirements for EOMs are wide ranging and include i) provision of the relatively slow vestibulo-ocular and optokinetic eye movement reflexes for baseline ocular stability, ii) effectuating pursuit and vergence eye movements to maintain fixation on slowly moving targets, as well as iii) providing rapid saccadic eye movements to quickly reorient the visual system to new targets. In humans, co-ordinate functioning of EOMs is critical for provision of binocular vision. Furthermore, the EOMs need to function on demand with high fidelity, for relatively long periods of time (7, 13) .
Since the functional demands on EOMs are quite different from those imposed on other skeletal muscles, it is not surprising that EOMs exhibit a number of distinctive properties (50) . For example, morphologically, physiologically or biochemically defined fiber types in EOMs do not correspond to those in other skeletal muscles (34, 47, 54 ). An array of unusual electro-mechanical features in EOMs result in fibers that have shorter contraction times, but lower tension generation when compared to other skeletal muscles (1, 2, 19, 32, 49) . Moreover, adult EOMs contain multiply innervated fibers; fibers that are uncommon in other mammalian skeletal muscles. The combination of fast contractile properties, high oxidative capacity and high fatigue resistance is unusual among skeletal muscles and further emphasizes the complexity of these muscles (7, 50) .
From a disease perspective, EOMs are preferentially involved in diseases such as the congenital cranial dysinnervation disorders, myasthenia gravis and mitochondrial myopathies (14, 23) . Conversely, EOMs remain clinically and anatomically spared in Duchenne's muscular dystrophy (DMD), despite the severe and widespread necrosis seen in other skeletal muscles in this disease (22, 26) . Indeed, EOMs remain functionally and anatomically spared even until death of patients with DMD. Unraveling the conundrum of clinical sparing of EOMs could prove of great clinical importance, since the molecular mechanisms utilized by human EOMs can potentially be translated into therapeutic strategies for DMD.
While it is currently unclear how EOMs achieve such specialization or why they have differential response to disease, it is generally accepted that the EOMs are inherently different in terms of their molecular makeup, and that the complement of genes expressed in EOMs contributes to their unique patho-physiological phenotype. Indeed the term "allotype" was coined to underscore the numerous EOM-group-specific properties (31) . Expression profiling of rodent EOMs suggests that systemic differences at the transcriptional level exist for this unique muscle group (15, 24, 41, 44) . Unfortunately, distinct and often dramatic differences in physiology (e.g. afoveate eyes, lack of binocular vision) and disease phenotype (e.g. the mdx mouse model for DMD does not have muscle wasting, indeed is actually stronger than littermates) make it difficult to transfer inferences drawn from rodent EOM studies to human EOM physiology and disease. Human EOMs differ significantly from other species with respect to fiber-type composition as well as expression patterns of myosin heavy chain (8, 28, 35, 48, 52) , sarco/endoplasmic reticulum calcium ATPase (4, 5, 27, 30) and laminin (29, 51) genes and/or their isoforms, indicating that significant inter-species differences exist at the molecular level.
To identify the molecular components underlying the unique properties of human EOM compared to other skeletal muscles, we performed expression profiling of normal human EOM and Quadriceps femoris (QF) limb muscle using Affymetrix (GeneChips) U133A high density oligonucleotide microarrays (ca. 22,000 human probe sets). Verification of expression changes was undertaken at RNA, protein and substrate level using a variety of cellular and molecular methods.
Materials & Methods

RNA Isolation
Two human EOMs (1478-93, referred to as EOM2 and 1545-93, referred to as EOM3) were obtained at autopsy from 14 and 72 year old females respectively, who had no identified neuromuscular disease at the time of death. Both independent samples consisted of the whole superior rectus EOM. Three Quadriceps femoris (QF) limb muscle biopsies (M5, M6 and M12) were from 5, 6 and 12 year old male patients with as yet unclassified neuromuscular disease at the Children's National Medical Center (Washington, DC). Two independent RNA preparations were made in the case of EOM and three individual preparations of QF for GeneChip screening. Fiber-typing of muscle was unremarkable. Total RNA was extracted using the TRIzol reagent (Gibco BRL Life Technologies, MD) and purified using the RNeasy kit (Qiagen, Hilden, Germany) following the manufacturer's instructions. Briefly, frozen muscle tissue was pulverized in liquid nitrogen using a mortar and pestle and transferred into TRIzol reagent. The solution was homogenized using a Polytron homogenizer (20 s at position 4.5, Kinematica, Kriens/Luzern, Switzerland). RNA was purified by phenol/chloroform extraction, precipitated using isopropyl alcohol and resuspended in diethyl pyrocarbonate (DEPC) treated water. This RNA solution was re-purified using the RNeasy kit and eluted with 40 µl of DEPC-treated water. An aliquot was used for quantification and verification of quality (260/280 ratio between 1.9-2.1) using a GeneQuant Pro spectrophotometer (Amersham Pharmacia Biotech, Upsalla, Sweden). All human tissue samples used in the study were obtained with appropriate institutional approvals and in accordance with the provisions of the Declaration of Helsinki for use of human tissue in research.
Affymetrix GeneChip Expression Profiling
Affymetrix human U133A series oligonucleotide based arrays were screened using guidelines provided by the manufacturers (http://www.affymetrix.com/support/technical/manual/expression_manual.affx) and as previously described, optimized for expression profiling of skeletal muscle (3, 12, 15) . Briefly, 5 µg of RNA was reverse transcribed and double stranded cDNA synthesized using the SuperScript Choice system (Invitrogen, Carlsbad, CA) with a hybrid oligo dT-primer containing the T7 RNA polymerase promoter (Genset, San Diego, CA). The double stranded cDNA was purified using phenol/chloroform extraction and precipitated with ethanol. This cDNA was resuspended in water and served as a template for an in vitro RNA transcription reaction using the ENZO BioArray High Yield RNA transcript (biotin) labeling kit (Enzo Diagnostics, Farmingdale, NY). An aliquot was quantified by spectrophotometry to calculate RNA yield and to ensure quality of in vitro transcription (in vitro transcribed RNA yield greater than 5x input). Biotin labeled cRNA transcripts were processed as per manufacturer's recommendation using an Affymetrix GeneChip Instrument System (Affymetrix). Briefly, the samples were purified using the RNeasy kit (Qiagen) and fragmented to ca. 200 bp size by incubating in 200 mM Tris-acetate pH 8.2, 500 mM KOAc, 150 mM MgOAc at 94°C for 35 minutes. Eukaryotic hybridization controls were added to each sample prior to hybridization to U133A GeneChips on an Affymetrix fluidics station 400 (16 hrs at 45°C and 60 rpm). Subsequently, the GeneChips were washed and stained on the fluidics station to detect hybridized cRNA using phycoerytherin conjugated streptavidin. The signal was amplified by a second round of staining and fluorescence read using a Hewlett-Packard G2500A Gene Array Scanner. Fluorescence data were analyzed using Microarray Suite 5.0 (Affymetrix). In brief, the intensity of one probe cell containing an oligonucleotide complementary to a specific sequence or perfect match (PM) was compared to the intensity of the adjacent probe cell which contains one mismatch (MM) in the center of the oligonucleotide. This analysis was repeated subsequently using multiple (11) probe pairs for each gene. The expression level of each gene was calculated based on a comparison of hybridization, i.e. of the PM vs. MM signal. Iterative comparisons of different GeneChips that had been processed in parallel were conducted using two independent EOM and three QF hybridizations leading to six data sets from five microarrays. Differential expression of genes with consistent fold changes ( 2-fold) in EOM and QF was detected by comparing these six independent data sets using previously described statistical methods that result in efficient detection of the most significant gene expression change (3, 12, 15) .
Briefly, the determination of whether a gene was differentially expressed in EOM compared to QF depended on the following parameters; absolute call (abs call), fold change (FC), and difference (diff) call. In turn, the data for these parameters were derived using a decision matrix, which calculated analysis metrics (positive fraction, positive/negative ratio, and log average ratio) and was dependent on the probe array's hybridization intensities. A probe set was defined as increased if it satisfied all of the following; abs call = P (present), FC 2, diff call = I (increased) or MI (marginally increased). A probe set was defined as decreased if it fulfilled all of the following; abs call = P (present), A (absent) or M (marginal) provided baseline A (absent), FC -2, and diff call = D (decreased) or MD (marginally decreased). Probe sets that survived these criteria in all 6 iterative comparisons were considered as having significant expression changes. The average values of these pair-wise comparisons are used throughout this study.
Semi-Quantitative RT-PCR
200 nanogram of total RNA from EOM and QF were reverse transcribed into cDNA using the Superscript Choice system (Gibco BRL). PCR was performed and aliquots removed at 22, 24, 26, 28 and 30 cycles to determine the linear amplification range of each gene, as previously described (15) . PCR products were resolved on 1.5% agarose gels and visualized using SYBR Green I (Molecular Probes, Eugene, OR) staining on the Typhoon™ 8600
PhosphorImager (Amersham Pharmacia Biotech, Uppsala, Sweden). Quantification was performed on aliquots that lay within the linear amplification range for each reaction and normalized against GAPDH by using ImageQuant 1.2 software (Amersham) for the Mac OS. The entire experiment was repeated including independent cDNA preparation, PCR and quantification steps.
Immunocytochemistry & Histochemistry
In addition to the samples used for profiling, autopsy samples from EOM and biopsy samples for limb muscles were obtained from individuals (ages 17-34) and used for independent biological validation by immunocytochemistry and histochemistry. The samples were mounted on cardboard, rapidly frozen in liquid nitrogen chilled isopentane and stored at -80 °C. Serial cross-sections (5 µm) were cut using a Reichert-Jung cryostat and processed for immunocytochemistry with previously characterized monoclonal antibodies (mAb)
recognizing the laminin lpha 4-chain, the laminin lpha 5-chain, the Na + /K + ATPase a1 subunit and MYH13. The tissue sections were processed as previously described (15) . Control sections were processed as above, except that the primary antibody was omitted. No staining was observed in the control sections.
Glycogen content was revealed using periodic acid-Schiff (PAS) reaction. Serial sections were pretreated with alpha amylase enzyme to control for specificity of the glycogen staining procedure. Mitochondria content was monitored using nicotinamide dehydrogenase tetrazolium reductase diaphorase (NADH-TR) staining. The sections were photographed under a Nikon microscope equipped with a CCD camera. The number of capillaries was noted in randomly chosen areas (500 µm 2 ) from sections stained with the antibody recognizing laminin lpha 5-chain. All vessels with an outer diameter less than 15 µm were scored as capillaries according to the criteria defined by Jerusalem and co-authors (21) .
Results
Expression Profiling of EOM and QF muscle
To define the expression profile of human EOM compared to limb muscle we screened the Affymetrix U133A GeneChips with RNA extracted from human EOM and QF. We chose rectus EOM and QF, since these muscles have been studied extensively and profiling data are already available for QF from normal and DMD patients (12, 17) . To verify lack of intra-sample variability, we determined the overall variability of expression profiles between two EOM and two QF samples. Scatter graphs of expression levels of all probe sets represented on individual microarrays compared either between the two EOM samples ( To analyze and interpret the data we performed iterative comparisons of the data sets as previously described (3, 12, 15) . Multiple (6) iterative comparisons using a two-fold difference cutoff were performed to control for intra-sample variability (e.g. in hybridization of cRNA) and to perform a stringent determination of significant and reproducible expression changes. Figure 2A shows six iterative comparisons of 'difference calls' from the five independent RNA preparations and hybridizations (2 EOM preparations and 3 QF preparations). The number of surviving increase and decrease calls (or differentially expressed genes) declines sequentially. Additionally, the total number of calls is stabilized by the sixth comparison, suggesting that additional comparisons would be unlikely to achieve greater stringency. This method revealed 222 upregulated and 144 downregulated transcripts in EOM compared to QF, based on a 2-fold difference cutoff. These transcripts represent 1.0% and 0.6% of the total probe sets that were screened (22215). Figure 2B shows a scatter graph displaying the fold changes in expression of transcripts that were differentially expressed between EOM vs. QF after imposing a +/-2 fold cut-off on the data (i.e. deleting all genes from the graph which were not found to be differentially expressed). All primary data have also been deposited in the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) database (accession number: GSE873).
Characterization of differentially expressed genes in EOM
Further analysis of the 366 probe sets revealed presence of some transcripts that could be readily ascertained as emanating from the same genetic loci (e.g. splice variants), reducing the actual number of differentially expressed genes to 338. Of the 204 upregulated genes in EOM, 149 were well characterized genes (representing 73.0% of upregulated genes; 0.7% of all probe sets screened) and 55 encoded genes of unknown function (representing 27.0% of upregulated genes; 0.2% of all probe sets screened). In case of the 134 genes that were found to be downregulated in EOM, 106 were previously described genes (representing 79.1% of downregulated genes; 0.5% of all probe sets screened) while 28 encoded genes of unknown function (representing 20.9% of downregulated genes; 0.1% of all probe sets screened). The set of genes of unknown function are not discussed in detail in this study, since their function has currently not been elucidated.
Nonetheless, since this set of genes helps to accurately and comprehensively define the EOM expression profile, this set is also listed as supplementary data on the following URL (To be specified by the Journal).
Additionally, profiling data was re-evaluated using different statistical methods and the (concordant) results are provided as Supplemental Support Statistical Tables (1-7 We tabulated and sorted the known, differentially expressed genes into various functional groups (Table 1) . Genes related to the protein biosynthesis (10.7%) and genes involved in intracellular signaling (8.3%) are the largest functional groups of all differentially expressed genes. Other groups include genes encoding neuronal proteins (7.7%) and sarcomeric elements (3.6%), genes involved in maintenance of intracellular homeostasis (2.1%), energy metabolism (4.4%), protein metabolism (5.0%) and genes related to growth, development and regeneration (3.0%). Interestingly, genes encoding development-related proteins within the vascular and neuronal groups make up 5.6% of all differentially expressed genes. Taken together, these data are consistent with the hypothesis that EOM has a unique molecular makeupand differs from that of limb muscle.
Validation of expression profiling: Structural & Metabolic elements
We used a number of independent methods to validate important functional components and predictions revealed from expression profiling of human EOMs. Expression levels of seven genes (MYH13, adducin gamma, Glycoprotein M6B (GPM6B), IGFBP6, Monoamine Oxidase A (MAOA), thromboplastin and thrombospondin) representing different functional groups were verified at the mRNA levels by RT-PCR (Fig.   3 ). Furthermore, a number of features of the the expression profile were also verified at the protein and/or substrate level (Fig. 4 ) using immunohistochemistry. The increased expression of the previously wellcharacterized EOM marker MYH13 (Fig. 2, Fig. 3 ) was also validated at the protein level using immunohistochemistry (Fig. 4, A characterized increased vascularity of EOM (7, 10) . Morphometric analysis based on counting six areas from the medial rectus EOM and three from QF (total of 1823 capillaries) revealed that EOM had ca. 5x higher abundance of capillaries compared to limb muscle. The increased expression of membrane channel Na+/K+ ATPase was validated using immunohistochemistry (Fig. 4 , G and H). Histochemical analysis of metabolic pathways using PAS (Fig. 4, I and J) and NADH-TR diaphorase activity (Fig. 4 , K and L) validated the well characterized low glycogen content coupled with increased mitochondrial oxidative pathway utilization (7, 9- 11) by EOM (Table 1) . Overall, the expression profile of EOM defined in this study correlates well with what is known about EOM structure and function, suggesting that our expression profiling was sensitive and comprehensive.
Discussion
In this study, we used Affymetrix GeneChip based transcriptome analysis to define the expression profile of human EOM compared to limb muscle. Three hundred and thirty eight (338) genes were found to be differentially expressed in EOM compared to QF muscle, defining the EOM profile. Verification of expression changes was undertaken at RNA, protein and metabolic level using a variety of cellular, molecular and histochemical methods. The use of multiple independent assays to validate major components of the EOM profile should afford a high degree of confidence for this study. Taken together, our results support the hypothesis that the overall pattern of gene expression or 'allotype' of human EOM is fundamentally different from that of limb muscle.
The last three years has seen a number of comparative analyses being performed on the rodent EOM due to the advent and advances in genetic technologies related to transcriptome analysis. Using a screening cum cloning technique called differential display, we had previously demonstrated that the rat EOM transcriptome was indeed different compared to limb muscle (41) . More recently, oligonucleotide microarrays (GeneChips) have been used to greatly extend these findings and compare expression levels of genes encoded by the ca. 10, 000 probe sets present on rat and mouse GeneChips, thus allowing interrogation of about a fourth of the rodent transcriptome (15, 24, 44 ).
The present study used GeneChip-based expression profiling to analyze and define the human EOM allotype. Since our knowledge of functional genomics and genetic disorders is greater in human compared to rodents, analysis of EOM and limb muscle from humans allowed a more comprehensive interrogation of the transcriptome. Indeed, the U133A series of Affymetrix GeneChips used in this study is about twice as informative as rodent-based GeneChips, since it allows interrogation of ca. 22, 000 probe sets covering all well characterized expressed genes or approximately half of the human transcriptome. As rodents lack a fovea or binocular vision in contrast to humans, definition of the human EOM allotype has greater relevance for understanding patho-physiological mechanisms of human EOM.
The expression profile obtained in this study was concordant with many known structural and metabolic features of EOM. Detection of MYH13 (Table 1 , Fig. 1, 3, 4) demonstrates the sensitivity of the approach since this well-characterized marker of EOM, while highly differentially regulated, is expressed at low abundance. Validation of the differential expression of a number of genes (MYH13, adducin, GPM6B, IGFBP6, MAOA, thromboplastin and thrombospondin) at the mRNA level (Fig. 3) demonstrates the specificity of the approach, since the genes occur in separate functional groups (Table 1) . Differential expression of genes encoding vessels, mitochondria and sets of metabolic enzymes provide transcriptomebased suggestions that human EOM preferentially utilize glucosefor energetically efficient oxidative phosphorylation (Table 1) . A number of genes related to growth/development and apoptosis were differentially expressed in EOM (Fig. 3 , Table 1 )This is interesting, since continual myogenesis in uninjured adult EOM has been suggested based on expression profiling, metabolic and/or satellite cell labeling studies in a variety of species including humans (15, (37) (38) (39) . Taken together these studies suggest that superior regeneration/myogenic potential may contribute to EOM sparing in DMD. The high degree of concordance with previous studies in other species as well as validation by structural, molecular and biochemical means, suggests that our molecular definition of human EOM allotype should provide mechanistic insights toward the functioning of this unique muscle.
Expression Profiling: Structural Elements
The expression profile obtained in this study was concordant with the known structural features of EOM (7, 13). The increased expression levels of MYH13 mRNA in human EOM is consistent with previous reports analyzing the distribution of the protein product (28) . The differential expression of genes that are known to modulate contractile properties of muscle such as tropomyosin 4, the essential light chain, myosin regulatory light chain interacting protein and caldesmon-1 was noted. A number of genes associated with calcium/calmodulin dependent signal transduction pathways involved with muscle contractility were differentially regulated in EOM as well. This is exemplified by differential regulation of genes such as calcineurin A-beta, calcipressin, adducin 3 and calsarcin-1. Interestingly calsarcin-1 binds the Z-disc protein alpha actinin in developing, cardiac and/or slow twitch muscle as well as calcineurin and thus could play an important role in tethering it to the sarcomere in EOM (16) . Genes related to neuronal outgrowth and synapse formation were upregulated, providing clues for development of multiply innervated fibers that are seen in EOMs ( Table 1 ). The specific combinatorial complement of structural proteins, calcium/calmodulin dependent signaling pathways and specialized innervation would be predicted to provide the EOM with unique contractile properties.
Expression Profiling: Conserved features of energy metabolism
Expression profiling of human EOM revealed features strikingly similar to those previously noted with respect to metabolic pathways in rodents (15, 24, 41, 44) . Consistent with the model of unidirectional glucosebased energy metabolism, we noted excessive downregulation of the gene encoding fructose-1,6-biphosphatase (F-1,6-BP), the key antagonist to the phosphofructokinase enzyme. Low levels of F-1,6-BP would be predicted to promote unidirectional glucose breakdown. The increased expression of vascular genes provide the mechanistic basis for increased vascularity; a structural feature of EOMs that would facilitate adequate availability of blood-borne glucose for metabolic needs. The EOMs are extremely vascular (7, 42) and possess the highest capillary density measured amongst human muscles (29) . Interestingly, levels of laminin mRNA were not found to be differentially expressed, which may be related to a wider sub-cellular distribution of the mRNA than protein, transcriptional/translational stability or the sensitivity of profiling for this gene. An important feature noted in our rat EOM profiling study was decreased glycogen content, coupled with decreased expression of key regulatory enzymes for glycogen synthesis and glycogen breakdown. This mechanism seems conserved in humans; the glycogen content of human EOM was also reduced in a manner comparable to what we had noted previously in rat EOM (15) . Expression levels of key regulatory enzymes of glycogen synthesis protein phosphatase 1, regulatory inhibitor subunit 2 (PPP1R2) and protein phosphatase 1, regulatory inhibitor subunit 1A (PPP1R1A), as well as phosphorylase kinase, the key regulator of glycogen breakdown were downregulated. Additionally, differential expression of the brain isoform of creatine kinase (CK-BB) as well as adenosine monophosphate deaminase 1 (AMPD1) was noted in EOM. Both these enzymes provide alternative pathways for energy metabolism and may play an important role for the unique contraction dynamics and properties of EOM that allow rapid contractions for extended periods of time.
Expression Profiling: Mitochondria & ROS metabolism
Additional support for the hypothesis that EOMs utilize oxidative rather then glycolytic pathways comes from the differential expression of genes encoding mitochondrial proteins. High levels of genes such as 3-oxoacid CoA transferase (OXCT),a mitochondrial matrix protein, as well as monoamine oxidase A (MAOA), an outer mitochondrial membrane protein, were detected in the EOMs. Interestingly, we also noted downregulation of the mitochondrial gene uncoupling protein (UCP3), a feature noted previously in rat EOMs as well. Since UCP3 catalyzes thermogenesis rather than ATP production, downregulation of UCP3 in EOMs suggests a mechanistic adaptation for efficient oxidative metabolism. The differential expression of genes related to energy metabolism suggests that energy utilization in human EOMs is similar to that proposed for rat EOMs, i.e. preferential, unidirectional, glucose-based oxidative metabolism dependent on blood-borne energy fuels rather then intracellular storages of glycogen.
Dependence of EOMs on oxidative metabolism is predicted to generate high levels of reactive oxygen species (ROS), which have the potential of causing significant cellular damage. The profiling data suggests that human EOMs have increased expression of genes encoding chemoprotective proteins such as P450
Cytochrome oxidoreductase (POR), CYP1B1, aldehyde dehydrogenase A3 (ALDH1A3) and aldehyde oxidase.
Since microsomal NADPH-dependent lipid peroxidation is triggered by passage of electrons from NADPH to ferric ions, the high expression level of POR mRNA would be predicted to attenuate the deleterious effects of . This is consistent with the notion that continuous EOM remodeling would be predicted to require remodeling of neural and vascular elements along with myofibres to retain full functionality. In general these features are similar to those noted previously while profiling rodent EOM (15) . Continual myogenesis in uninjured adult EOM has also been independently suggested and validated directly using satellite cell and apoptotic cell labeling studies, in a variety of species including humans (36) (37) (38) (39) 53) . Conservation of this important property across species signifies the inherent importance that continual myogenesis/remodeling plays in these unique muscles.
Expression Profiling: Disease Perspective
Since the functional demands on EOMs are distinct from those on other skeletal muscles, it is not surprising that the EOMs possess a unique set of structural and metabolic adaptations as reflected by their expression profile. What is surprising is the differential sensitivity to certain diseases, which seems in part a functional consequence of their unique expression profile. Differential expression of genes related to energy metabolism suggests a model in which human EOM preferentially utilize glucose-based oxidative metabolism dependent on blood-borne energy fuels rather then intracellular storages of glycogen. In humans, inability of muscle to metabolize glycogen causes McArdle's disease. This disease presents with painful exercise-induced cramps in limb muscles; however, the EOM remain unaffected. The relative independence from glycogen as an energy source (as opposed to limb muscle) offers an explanation why EOMs are spared in this disease.
Ironically, these adaptations are predicted to render the EOMs vulnerable to disorders of oxidative metabolism.
Indeed EOMs are involved early, frequently and prominently in the mitochondrial myopathies, where oxidative metabolism is compromised due to genetic mutations of mitochondrial genes (7, 13) .
EOMs are functionally (22) and anatomically spared in DMD (26) . This sparing presents an intriguing conundrum since we have previously shown that both normal human limb muscle and EOM produce full-length dystrophin, and that dystrophin is completely absent in both limb and EOM of DMD patients (26) . This phenomenon extends across species as EOMs are spared in the canine (26) and murine (mdx) models of DMD as well (26, 33, 45) . A number of hypotheses have been proposed to explain EOM sparing in DMD, and seem to converge on the notion that EOM group-specific properties prevent, adapt or compensate against dystrophin deficiency (25, 43) . Unfortunately, independent tests of many of these hypotheses have yielded equivocal results. EOM-specific utrophin upregulation was suggested to be protective based on mouse studies (33, 45) . However, studies from our laboratory have demonstrated that utrophin is not upregulated in EOMs of normal or dystrophic mice, dogs or humans at the protein level (26) . Additionally, no evidence has been found for utrophin mRNA upregulation at the transcriptome level in studies performed either at our laboratory (15) or other laboratories (24, 44) in rats or mice. The current profiling study also failed to find evidence for utrophin upregulation in human EOMs. Taken together, it is unlikely that utrophin upregulation plays a role in sparing of EOMs in DMD. Higher antioxidant capacity (46) and/or enhanced capacity for calcium homeostasis (26) have been suggested to play a protective role and the current profiling data support this hypothesis. The current profiling study supports the hypothesis that human EOMs have superior regeneration/myogenesis and constant remodeling (37) . Indeed, increasing myogenesis/regeneration using pharmacological myostatin-blockade has been shown to ameliorate the dystrophic phenotype in the mouse model of muscular dystrophy (6).
In conclusion, we used a variety of molecular and structural methods to identify, validate and help define the molecular determinants of the unique EOM allotype in humans. Our current study showed a high degree of concordance with profiling studies that defined the rodent EOM allotype. The concordance was somewhat surprising since inter-species differences of the visual system between rodents and humans are quite pronounced; rodents have a simpler visual system lacking a fovea and do not use binocular vision.
Comparative studies in non-mammalian species may help clarify this issue. The expression profile and biochemical data presented in this study suggests the preferential use of glucose-based, aerobic metabolic pathways in EOM. The study supported the hypothesis that human EOMs have superior regeneration/myogenesis and constant ongoing remodeling presumably is due to an increased complement of satellite and/or stem cells. We believe that our definition of the EOM-specific expression profile will help provide a more mechanistic understanding of the distinct metabolic and patho-physiological properties of EOM. comparisons between EOM and limb muscle on a log scale after imposing a two-fold cutoff. Individual points on the graph represent genes, which met the twofold difference cutoff (i.e. differentially expressed genes).
Figure Legends
Genes lying off the diagonal show the greatest differences in expression between EOM and limb muscle. 
